Novartis AG (NVS) moved down by 3.16%. The Pharmaceuticals & Medical Research sector is down by 0.41%. The company underperformed the industry. Top 3 stocks by turnover in the sector: Novartis AG (NVS) down 3.16%; Johnson & Johnson (JNJ) down 0.19%; Eli Lilly and Co (LLY) down 0.28%.
What is driving Novartis AG (NVS)’s stock price down today?
Novartis (NVS) experienced downward pressure on its share price today, largely attributable to the stock trading ex-dividend. The ex-dividend date, March 11, 2026, means that investors purchasing shares on or after this date are not entitled to the recently declared dividend of $4.773 per share. Such events typically result in a corresponding reduction in the stock's price, reflecting the value being paid out to eligible shareholders.
This specific event occurred amidst broader, recent developments for the company. Novartis had previously announced its fourth-quarter 2025 financial results, where it reported earnings per share (EPS) that surpassed analyst expectations. However, its reported revenue for the quarter did not meet the anticipated figures. Furthermore, in early February, Novartis issued a forecast for its 2026 operating profit, projecting a low single-digit percentage decline. This outlook signaled that 2026 could be a transitional year for the pharmaceutical giant, partly due to patent expiries of key drugs.
Adding to the mixed sentiment, several analyst firms adjusted their ratings in recent weeks. While Argus upgraded Novartis to a "Buy" rating today, citing an attractive entry point after a recent pullback, other firms like DZ Bank and Wall Street Zen had previously downgraded the stock in early February.
Despite these pressures, the company has also seen some positive news, including the recent completion of the acquisition of Avidity Biosciences and positive Phase 3 clinical trial results for Vanrafia in IgA nephropathy. However, the impact of the stock going ex-dividend is often a direct and significant factor in short-term price movements.
Technical Analysis of Novartis AG (NVS)
Technically, Novartis AG (NVS) shows a MACD (12,26,9) value of [4.03], indicating a neutral signal. The RSI at 53.45 suggests neutral condition and the Williams %R at -62.11 suggests oversold condition. Please monitor closely.
Fundamental Analysis of Novartis AG (NVS)
Novartis AG (NVS) is in the Pharmaceuticals & Medical Research industry. Its latest annual revenue is $56.33B, ranking 9 in the industry. The net profit is $13.98B, ranking 5 in the industry. Company Profile
Over the past month, multiple analysts have rated the company as Hold, with an average price target of $136.67, a high of $175.00, and a low of $112.00.
More details about Novartis AG (NVS)
Company Specific Risks:
- Novartis faces ongoing financial and reputational implications from the recent, undisclosed settlement of a lawsuit by the Henrietta Lacks estate, signaling continued scrutiny over historical biomaterial sourcing practices within the pharmaceutical industry.
- The company anticipates facing the "largest impact from loss of exclusivity" for key revenue-generating products like Entresto, Promacta, and Tasigna in 2025 and 2026, leading to significant revenue erosion and contributing to a Q4 2025 revenue miss against analyst expectations.
- Increased competitive pressure in therapeutic areas such as IgA nephropathy, with the recent positive phase III interim data from rival therapies like Vertex's povetacicept, poses a threat to the market share and revenue potential of Novartis's Fabhalta.
- Mixed analyst sentiment, including concerns over the stock's valuation (P/E, P/S, P/B ratios near historical highs), suggests skepticism regarding Novartis's ability to effectively integrate acquisitions and launch new products to adequately offset the financial impact of patent expirations.
Find out more
Comments